Bold 250 is an oily solution of boldenone undecylenate for IM injection. Bold 250 is designed to release
boldenone slowly from the injection site. Boldenone serum levels will remain elevated for 5 to 8 days after
administration. Boldenone is an anabolic steroid possessing anabolic properties with moderate androgenic
activity. Anabolic and androgenic agents are widely used in the treatment of catabolic processes where
accelerated strength and muscular development are indicated.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved.
The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH).
At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
Pharmacological studies involving laboratory animals have demonstrated boldenone to have potent anabolic properties as well as moderate androgenic activity. In clinical trials boldenone demonstrated a moderate to strong anabolic effect, improved appetite, increased vigor, and improved musculature and strength.
Bold 250 is indicated as an alternate or adjunctive therapy in patients for the promotion of weight gain following
weight loss and/or muscular atrophy associated with extensive surgery, chronic infections, long term hospitalization, or severe trauma.
For increased RBC in severe anemic patients where first-line therapy is contraindicated.
For promotion of increased appetite in patients with appetite limited intake.
Boldenone should be considered only as an adjunctive therapy together with other androgenic medications.
DOSAGE AND ADMINISTRATION
Dosage has not been established. Use only pursuant to instructions of a qualified physician.
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms,
peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
Patients with known hypersensitivity to any ingredients in this product.
Patients with known or suspected carcinomas of the breast, testis, or prostate.
Patients with severe heart disease, liver disease, or kidney disease or with a history of epilepsy.
Products containing androgens should not be used in women as they may cause virilization and fetal harm.
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol.
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use.
Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with
difficulty in urination or with changes in voiding habits.
No human trials have been conducted. In the absence of data on the effect of this drug on human subjects,
such use should be on a research basis only under the supervision of a qualified physician.
Bold 250 (250mg/ml) - 10ml multiple dose vial OR 10 ampules of 1ml each.
Protect from light, store at 15-25oC.
PRODUCT AUTHENTICATION :
NEWS / EVENTS
Magnum Pharmaceuticals Authentication
Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.
Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.
Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.